+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
BioCryst Pharmaceuticals Inc - logo

BioCryst Pharmaceuticals is a biotechnology company that designs and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst's core development programs include BCX7353 and additional 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema; and BCX4430 (GALIDESIVIR), a broad spectrum antiviral for hemorrhagic fevers. The company was founded in 1986 and is headquartered in Durham, North Carolina.

From
Market Spotlight: Hereditary Angioedema - Product Thumbnail Image

Market Spotlight: Hereditary Angioedema

  • Report
  • March 2021
  • 43 Pages
ROI in Pharmaceutical R&D: How to Halt the Decline - Product Thumbnail Image

ROI in Pharmaceutical R&D: How to Halt the Decline

  • Report
  • December 2019
  • 196 Pages
From
From
ACVR1 protein inhibitors - Pipeline Insight, 2022 - Product Thumbnail Image

ACVR1 protein inhibitors - Pipeline Insight, 2022

  • Drug Pipelines
  • January 2022
  • 60 Pages
From
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2020 - Product Thumbnail Image

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 140 Pages
From
From
From
From
From
From
Activin Receptor Type 1 - Pipeline Review, H1 2020 - Product Thumbnail Image

Activin Receptor Type 1 - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 70 Pages
From
From
From
Yellow Fever Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Yellow Fever Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • October 2018
  • 57 Pages
From
Angioedema Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Angioedema Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • October 2018
  • 125 Pages
From
Loading Indicator